The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04.
Atsushi Makimoto
No relevant relationships to disclose
Motoaki Chin
No relevant relationships to disclose
Minako Sumi
No relevant relationships to disclose
Ryohei Yokoyama
No relevant relationships to disclose
Tsuyoshi Ishida
No relevant relationships to disclose
Hajime Okita
No relevant relationships to disclose
Akinobu Matsuzaki
No relevant relationships to disclose
Atsushi Kikuta
No relevant relationships to disclose
Hiroyoshi Watanabe
No relevant relationships to disclose
Toshifumi Ozaki
No relevant relationships to disclose
Kazuo Isu
No relevant relationships to disclose
Michihiro Yano
No relevant relationships to disclose
Masahito Hatori
No relevant relationships to disclose
Masahito Tsurusawa
No relevant relationships to disclose
Hideaki Ohta
No relevant relationships to disclose
Yoshifumi Kawano
No relevant relationships to disclose
Takeshi Ishii
No relevant relationships to disclose
Hiroshi Kawamoto
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Hideo Mugishima
No relevant relationships to disclose